肿瘤细胞治疗研究
英文原题：Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies.
Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
巨细胞病毒（CMV）仍然是异基因造血细胞移植（HCT）后患者最重要的病毒病原体，导致发病率和死亡率。
巨细胞病毒（CMV）仍然是异基因造血细胞移植（HCT）后患者中最重要的病毒病原体，导致发病率和死亡率。欧洲白血病感染会议（ECIL）汇集了多个领域的专家，通过全面的文献综述制定循证建议。CMV的管理此前已被讨论过两次；ECIL上一次指南更新发表于2019年。2024年第10届ECIL会议讨论了异基因HCT后CMV管理的新进展，本综述呈现了相关建议。管理建议包括诊断，如免疫监测、来特莫韦抗病毒预防、耐药和难治性CMV感染的管理，以及CMV管理的儿科方面。此外，第10届ECIL引入了两个新类别的建议：接受CAR-T 细胞治疗的患者或接受双特异性T细胞衔接抗体治疗的患者。
Cytomegalovirus (CMV) remains the most important viral pathogen in patients after allogeneic haematopoietic cell transplantation (HCT), resulting in morbidity and mortality. The European Conference on Infections in Leukaemia (ECIL) brings together experts in several fields to produce evidence-based recommendations from comprehensive literature reviews. Management of CMV has been addressed twice before; the previous guideline update from the ECIL was published in 2019. The 10th ECIL meeting in 2024 addressed new developments in CMV management after allogeneic HCT, and recommendations are presented in this Review. Management recommendations include diagnostics, such as immune monitoring, antiviral prophylaxis with letermovir, management of resistant and refractory CMV infections, and paediatric aspects of CMV management. Furthermore, the 10th ECIL introduced recommendations for two new categories: patients treated with chimeric antigen receptor T cells or treated with bispecific T-cell-engaging antibodies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
